Replies to post #13719 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Just to add to connecting the Libigel dots. Biosante in all likelihood is sitting on this CV story until meeting with the FDA regarding subset analysis. If positive they will release the information of subset analysis, this will cause a big bump in price. Once the final safety hurdle is passed they will probably confirm the CV benefit and the potential market in addition to the safety results.

Seeing that in October 2011 Biosante had an average 1 year target price of $6, with Libigel closer to NDA submission, the CV benefit and consider that GVAX was a non issue just coming off a HOLD. Your guess is as good as mine as to how high BPAX could go.

Very tasty food for thought.